RNAZ has 36-month beta value of 1.54. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNAZ is 20.98M, and currently, short sellers hold a 4.95% ratio of that float. The average trading volume of RNAZ on May 06, 2025 was 9.30M shares.
RNAZ) stock’s latest price update
TransCode Therapeutics Inc (NASDAQ: RNAZ)’s stock price has gone decline by -17.51 in comparison to its previous close of 0.51, however, the company has experienced a 0.17% increase in its stock price over the last five trading days. prnewswire.com reported 2025-05-05 that BOSTON, May 5, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split.
RNAZ’s Market Performance
TransCode Therapeutics Inc (RNAZ) has seen a 0.17% rise in stock performance for the week, with a -8.59% decline in the past month and a -94.37% plunge in the past quarter. The volatility ratio for the week is 23.61%, and the volatility levels for the past 30 days are at 23.01% for RNAZ. The simple moving average for the past 20 days is 6.72% for RNAZ’s stock, with a -95.05% simple moving average for the past 200 days.
RNAZ Trading at -58.14% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.36% of loss for the given period.
Volatility was left at 23.01%, however, over the last 30 days, the volatility rate increased by 23.61%, as shares sank -7.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -94.77% lower at present.
During the last 5 trading sessions, RNAZ rose by +0.17%, which changed the moving average for the period of 200-days by -98.63% in comparison to the 20-day moving average, which settled at $0.3959. In addition, TransCode Therapeutics Inc saw -87.46% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
The total capital return value is set at 0.01. Equity return is now at value -490.03, with -268.85 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated -0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -348.28. The debt to equity ratio resting at -0.02. The interest coverage ratio of the stock is -584.07.
Currently, EBITDA for the company is -14.03 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.56.
Conclusion
To put it simply, TransCode Therapeutics Inc (RNAZ) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
